DIAGNOSTIC ASSAYS FOR NEURODEGENERATIVE DISEASES
    4.
    发明申请
    DIAGNOSTIC ASSAYS FOR NEURODEGENERATIVE DISEASES 审中-公开
    神经病变性疾病诊断测定

    公开(公告)号:WO2005116239A3

    公开(公告)日:2006-06-01

    申请号:PCT/GB2005050075

    申请日:2005-05-27

    CPC classification number: G01N33/6896 C12Q1/46 G01N2500/00 G01N2800/28

    Abstract: The invention provides a simple colorimetric assay method for screening for propensity for, or occurrence of, neurodegeneration in the brain. The assay relies on measuring enzymatic activity of a soluble monomeric form of acetylcholinesterase (G 1 -AChE) added to biological samples such as serum or plasma samples. Exogenous G 1 -AChE with such samples from patients with, for example, Motor Neurone Disease associated with amyotrophic lateral sclerosis, Parkinson's disease or Alzheimer's disease has selectively been found to exhibit significantly higher activity than in similarly treated control samples.

    Abstract translation: 本发明提供了一种简单的比色测定方法,用于筛选脑中神经变性的倾向或发生。 该测定依赖于测量添加到生物样品如血清或血浆样品中的可溶性单体形式的乙酰胆碱酯酶(GNA 1 -AChE)的酶活性。 选择性地发现具有例如与肌萎缩性侧索硬化相关的运动神经元疾病,帕金森病或阿尔茨海默病的患者的这些样品的外源性G-1hHE表现出比类似处理的对照中显着更高的活性 样本。

    ALZHEIMER'S DISEASE ASSAY
    6.
    发明申请
    ALZHEIMER'S DISEASE ASSAY 审中-公开
    阿尔茨海默病

    公开(公告)号:WO01090757A1

    公开(公告)日:2001-11-29

    申请号:PCT/GB2001/002229

    申请日:2001-05-21

    Abstract: The present invention relates to a method for the detection of a marker protein (acetylcholinesterase or amyloid beta precursor protein) in a sample of saliva, that may be used as a diagnostic test for Alzheimer's disease or as marker of response to therapeutic intervention of a patient.

    Abstract translation: 本发明涉及用于检测唾液样品中的标记蛋白(乙酰胆碱酯酶或淀粉样蛋白β前体蛋白)的方法,其可用作阿尔茨海默病的诊断试验或作为对患者的治疗性干预的响应的标志物 。

    POTENCY ASSAY FOR SKELETAL MUSCLE DERIVED CELLS
    9.
    发明申请
    POTENCY ASSAY FOR SKELETAL MUSCLE DERIVED CELLS 审中-公开
    骨骼肌细胞衍生细胞的测定

    公开(公告)号:WO2014044867A1

    公开(公告)日:2014-03-27

    申请号:PCT/EP2013/069818

    申请日:2013-09-24

    Abstract: The present invention relates to a potency assay for skeletal muscle derived cells (SMDC), the potency assay comprises the steps of (a) measuring ACh E activity of SMDC, and (b) evaluating the potential of the SMDC to be used for the treatment of skeletal muscle dysfunction based on the AChE activity measured in step (a). Moreover, the present invention relates to skeletal muscle derived cells (SMDC) for use in the treatment of a muscle dysfunction. Finally, the present invention relates to the use of AChE activity as an in vitro differentiation marker for skeletal muscle derived cells and to a kit for performing the potency assay according to the present invention.

    Abstract translation: 本发明涉及骨骼肌来源的细胞(SMDC)的效力测定法,其功效测定包括以下步骤:(a)测量SMDC的AChE活性,和(b)评估用于治疗的SMDC的潜力 的基于在步骤(a)中测量的AChE活性的骨骼肌功能障碍。 此外,本发明涉及用于治疗肌肉功能障碍的骨骼肌来源的细胞(SMDC)。 最后,本发明涉及AChE活性作为骨骼肌来源的细胞的体外分化标记物和用于进行根据本发明的效力测定的试剂盒的用途。

Patent Agency Ranking